JP2010143941A5 - - Google Patents

Download PDF

Info

Publication number
JP2010143941A5
JP2010143941A5 JP2010019796A JP2010019796A JP2010143941A5 JP 2010143941 A5 JP2010143941 A5 JP 2010143941A5 JP 2010019796 A JP2010019796 A JP 2010019796A JP 2010019796 A JP2010019796 A JP 2010019796A JP 2010143941 A5 JP2010143941 A5 JP 2010143941A5
Authority
JP
Japan
Prior art keywords
tumor
aminophospholipid
binding
antibody
binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010019796A
Other languages
English (en)
Japanese (ja)
Other versions
JP5478285B2 (ja
JP2010143941A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010143941A publication Critical patent/JP2010143941A/ja
Publication of JP2010143941A5 publication Critical patent/JP2010143941A5/ja
Application granted granted Critical
Publication of JP5478285B2 publication Critical patent/JP5478285B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2010019796A 1998-07-13 2010-01-29 アミノリン脂質に結合する結合体を用いる腫瘍血管系の処置および画像化 Expired - Fee Related JP5478285B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9258998P 1998-07-13 1998-07-13
US60/092,589 1998-07-13
US11060098P 1998-12-02 1998-12-02
US60/110,600 1998-12-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000558846A Division JP2002520297A (ja) 1998-07-13 1999-07-12 アミノリン脂質に結合する治療結合体を用いる癌処置方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012262623A Division JP5721693B2 (ja) 1998-07-13 2012-11-30 アミノリン脂質に結合する治療結合体を用いる癌処置方法

Publications (3)

Publication Number Publication Date
JP2010143941A JP2010143941A (ja) 2010-07-01
JP2010143941A5 true JP2010143941A5 (https=) 2011-05-19
JP5478285B2 JP5478285B2 (ja) 2014-04-23

Family

ID=26785826

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000558846A Pending JP2002520297A (ja) 1998-07-13 1999-07-12 アミノリン脂質に結合する治療結合体を用いる癌処置方法
JP2010019796A Expired - Fee Related JP5478285B2 (ja) 1998-07-13 2010-01-29 アミノリン脂質に結合する結合体を用いる腫瘍血管系の処置および画像化
JP2012262623A Expired - Fee Related JP5721693B2 (ja) 1998-07-13 2012-11-30 アミノリン脂質に結合する治療結合体を用いる癌処置方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000558846A Pending JP2002520297A (ja) 1998-07-13 1999-07-12 アミノリン脂質に結合する治療結合体を用いる癌処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012262623A Expired - Fee Related JP5721693B2 (ja) 1998-07-13 2012-11-30 アミノリン脂質に結合する治療結合体を用いる癌処置方法

Country Status (12)

Country Link
US (6) US7067109B1 (https=)
EP (1) EP1098665B9 (https=)
JP (3) JP2002520297A (https=)
AT (1) ATE230614T1 (https=)
AU (1) AU750414B2 (https=)
BR (1) BR9912053A (https=)
CA (1) CA2331789C (https=)
DE (1) DE69904831T2 (https=)
ES (1) ES2188202T3 (https=)
IL (1) IL140700A0 (https=)
NZ (1) NZ508873A (https=)
WO (1) WO2000002587A1 (https=)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814464A (en) * 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
KR20010020443A (ko) 1997-04-30 2001-03-15 캐서린 구 생체내 세포 치사를 이미지화시키는 방법
US7569674B2 (en) * 1998-05-04 2009-08-04 Innexus Biotechnology International Limited Autophilic antibodies
US20040185039A1 (en) * 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US20050033033A1 (en) * 1998-05-04 2005-02-10 Heinz Kohler Trans-membrane-antibody induced inhibition of apoptosis
US6300308B1 (en) * 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
US20090208418A1 (en) * 2005-04-29 2009-08-20 Innexus Biotechnology Internaltional Ltd. Superantibody synthesis and use in detection, prevention and treatment of disease
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US7067109B1 (en) 1998-07-13 2006-06-27 Board Of Regents, The University Of Texas System Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
CA2333147C (en) * 1998-07-13 2012-02-07 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6406693B1 (en) * 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
EP1520588B1 (en) 1998-07-13 2014-12-24 Board Of Regents, The University Of Texas System Uses of antibodies to aminophospholipids for cancer treatment
US6361774B1 (en) * 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
US6602274B1 (en) * 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US6521424B2 (en) * 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
CA2401411A1 (en) * 1999-08-30 2001-03-08 Mustapha Abdelouahed Diagnostic assay for type 2 heparin-induced thrombocytopenia
US6777439B2 (en) * 2000-05-30 2004-08-17 Advanced Research & Technology Institute, Inc. Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
US7445802B2 (en) * 2000-12-26 2008-11-04 Yeda Research And Development Co. Ltd Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
US20040001822A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7132510B2 (en) * 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7635680B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US20090291086A1 (en) * 2001-02-21 2009-11-26 Alavita Pharmaceuticals, Inc. Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
WO2002067857A2 (en) * 2001-02-21 2002-09-06 Surromed, Inc. Modified annexin proteins and methods for preventing thrombosis
CA2443314C (en) * 2001-04-03 2006-03-21 The Board Of Trustees Of The Leland Stanford Junior University Method of imaging cell death in vivo
WO2002080754A2 (en) * 2001-04-03 2002-10-17 Theseus Imaging Corporation Methods for using annexin for detecting cell death in vivo and treating associated conditions
US20050013778A1 (en) * 2001-04-03 2005-01-20 Theseus Imaging Corporation Methods and compositions for predicting the response to a therapeutic regimen in a subject having a disease associated with cell death
DE10127712A1 (de) * 2001-06-07 2002-12-19 Torsten Witte Anwendung von IgM-Antikörpern gegen dsDNA beim systemischen Lupus erythematodes mit Nephritis
US6763760B2 (en) * 2001-07-03 2004-07-20 Hansen Conly L Machine for injecting liquids
DE10145254A1 (de) * 2001-09-13 2003-04-10 November Ag Molekulare Medizin Verwendung eines Proteins zur Herstellung eines Medikaments zur Stimulierung einer inflammatorischen zellulären Immunantwort
WO2003028840A2 (en) * 2001-09-27 2003-04-10 Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
US8158106B2 (en) * 2001-10-05 2012-04-17 Surmodics, Inc. Particle immobilized coatings and uses thereof
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
JP4242590B2 (ja) * 2002-01-11 2009-03-25 俊一 塩澤 慢性関節リウマチの疾患感受性遺伝子、及びその利用
US20030133938A1 (en) * 2002-01-15 2003-07-17 Penichet Manuel L. Antibody-avidin fusion proteins as cytotoxic drugs
US6982154B2 (en) 2002-02-21 2006-01-03 Surromed, Inc. Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
US9745380B2 (en) * 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
US20040022731A1 (en) * 2002-04-26 2004-02-05 Alexei Bogdanov In vivo imaging of apoptosis
ATE510553T1 (de) * 2002-05-17 2011-06-15 Univ Texas Beta-2-glycoprotein 1 als angiogenesehemmer
AU2003237870A1 (en) * 2002-06-07 2003-12-22 The Brigham & Women's Hospital, Inc. Method and composition for inhibing or slowing blood coagulation
US20040208877A1 (en) * 2002-07-01 2004-10-21 Avigdor Levanon Antibodies and uses thereof
RU2005101622A (ru) * 2002-07-01 2006-01-27 Савиент Фармасьютикалс, Инк (Us) Композиции и способы терапевтического лечения
US20040202665A1 (en) * 2002-07-01 2004-10-14 Janette Lazarovits Compositions and methods for therapeutic treatment
KR20120068769A (ko) * 2002-07-15 2012-06-27 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
US7511124B2 (en) 2002-07-15 2009-03-31 Board Of Regents, The University Of Texas System Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents
US7378386B2 (en) * 2002-07-15 2008-05-27 Board Of Regents, The University Of Texas System Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives
US7572448B2 (en) * 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Combined cancer treatment methods using selected antibodies to aminophospholipids
US7611704B2 (en) 2002-07-15 2009-11-03 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids
US7455833B2 (en) 2002-07-15 2008-11-25 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
US7906115B2 (en) * 2002-07-15 2011-03-15 Thorpe Philip E Combinations kits and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids
US7790159B2 (en) 2002-07-15 2010-09-07 Board Of Regents, The University Of Texas System Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipids
US20040131622A1 (en) * 2002-07-15 2004-07-08 Board Of Regents Combinations and kits for treating viral infections using immunoconjugates to aminophospholipids
US7622118B2 (en) * 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
US7247303B2 (en) * 2002-07-15 2007-07-24 Board Of Regents, The University Of Texas System Selected antibody CDRs for binding to aminophospholipids
US7879801B2 (en) * 2002-07-15 2011-02-01 Board Of Regents, The University Of Texas System Compositions comprising cell-impermeant duramycin derivatives
US7615223B2 (en) * 2002-07-15 2009-11-10 Board Of Regents, The University Of Texas System Selected immunoconjugates for binding to aminophospholipids
US7384909B2 (en) * 2002-07-15 2008-06-10 Board Of Regents, The University Of Texas System Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents
US7625563B2 (en) * 2002-07-15 2009-12-01 Board Of Regents, The University Of Texas System Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
US7678386B2 (en) * 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
US7714109B2 (en) * 2002-07-15 2010-05-11 Board Of Regents, The University Of Texas System Combinations and kits for cancer treatment using selected antibodies to aminophospholipids
WO2004013303A2 (en) * 2002-08-02 2004-02-12 Surromed, Inc. Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease
US20040042959A1 (en) * 2002-08-28 2004-03-04 Michael Montalto Imaging cell death in vivo using non-radionuclide contrast agents
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
US20040191215A1 (en) * 2003-03-25 2004-09-30 Michael Froix Compositions for induction of a therapeutic response
CN1816356A (zh) 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
US20110002978A1 (en) 2003-06-17 2011-01-06 Harrison Roger G Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof
US20070207158A1 (en) * 2003-06-17 2007-09-06 Harrison Roger G Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof
EP1638989B1 (en) 2003-06-25 2008-07-30 Peregrine Pharmaceuticals, Inc. Method and apparatus for continuous large-scale radiolabeling of proteins
US7771956B2 (en) * 2003-06-30 2010-08-10 Brigham & Women's Hospital, Inc. Method for detecting the presence of a phospholipid
US20050152906A1 (en) * 2003-06-30 2005-07-14 Avigdor Levanon Specific human antibodies
US20050069955A1 (en) * 2003-06-30 2005-03-31 Daniel Plaksin Antibodies and uses thereof
DE10338733A1 (de) * 2003-08-22 2005-03-24 Berdel, Wolfgang E., Prof. Dr.med. Fusionspolypeptide und deren Verwendung für die antivaskuläre Tumortherapie
WO2005069935A2 (en) * 2004-01-20 2005-08-04 University Of Medicine And Dentistry Of New Jersey METHODS FOR MEASURING TRANSFORMING GROWTH FACTOR BETA (TGF-β) RECEPTOR SIGNALING ACTIVITY AND USES THEREOF
WO2005079831A1 (en) * 2004-02-13 2005-09-01 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hcnp peptides for the modulation of cardio-vascular physiology and diuresis
US20060003020A1 (en) * 2004-03-11 2006-01-05 The Regents Of The University Of Michigan Anti-metastatic ability of mibefradil and gadolinium
AU2005221195B2 (en) * 2004-03-11 2011-05-19 Alavita Pharmaceuticals, Inc. Modified annexin proteins and methods for preventing thrombosis
JP2008505853A (ja) 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
JP5139058B2 (ja) * 2004-06-02 2013-02-06 シドニー キンメル キャンサー センター 新形成または新生脈管構造の検出、画像化および処置のための血管標的
US20050271726A1 (en) * 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
EP1755686A2 (en) * 2004-06-02 2007-02-28 Sidney Kimmel Cancer Center Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface
US7511016B2 (en) * 2004-07-07 2009-03-31 Mosamedix B.V. Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
US20060127311A1 (en) * 2004-11-17 2006-06-15 Duke University Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer
US20080119367A1 (en) * 2004-12-17 2008-05-22 Mayo Foundation For Medical Education And Research Prognosis of Renal Cell Carcinoma
ZA200705695B (en) 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
CN101146826A (zh) * 2005-01-24 2008-03-19 得克萨斯大学体系董事会 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途
ES2503719T3 (es) 2005-02-11 2014-10-07 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
US7393833B2 (en) 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains
EP1712241A1 (en) * 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Composition for treating cancer adapted for intra-tumoral administration and uses thereof
EP1874334A4 (en) * 2005-04-15 2011-03-30 Vascular Biogenics Ltd COMPOSITIONS WITH BETA 2-GLYCOPROTEIN I-PEPTIDES FOR THE PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES
US20060257317A1 (en) * 2005-05-04 2006-11-16 Duke University Combination therapy in the treatment of cancer
RU2423381C2 (ru) 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
CA3000520C (en) 2005-08-24 2023-04-04 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
US20070225213A1 (en) * 2006-03-23 2007-09-27 Kosak Matthew K Nucleic acid carriers for delivery of therapeutic agents
WO2007117432A2 (en) * 2006-03-30 2007-10-18 The Regents Of The University Of Michigan Methods and compositions for modulating angiogenesis and tumor growth
US9789161B2 (en) * 2006-04-28 2017-10-17 Warsaw Orthopedic, Inc. Methods for treating back or neck pain caused by NGF using a therapeutic agent consisting of ReN-1820, ALE-0540 and capsaicin
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US9274129B2 (en) * 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US9217749B2 (en) * 2006-05-31 2015-12-22 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
US8840882B2 (en) * 2006-06-23 2014-09-23 Quintessence Biosciences, Inc. Modified ribonucleases
WO2008010991A2 (en) 2006-07-17 2008-01-24 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
ES2629749T3 (es) 2006-10-04 2017-08-14 Dana-Farber Cancer Institute, Inc. Inmunidad tumoral
US8518870B2 (en) * 2007-02-19 2013-08-27 The Board Of Regents Of The University Of Oklahoma Compositions and methods for cancer treatment using targeted carbon nanotubes
US9504745B2 (en) 2007-02-19 2016-11-29 The Board Of Regents Of The University Of Oklahoma Compositions and methods for cancer treatment using targeted carbon nanotubes
US20090324596A1 (en) 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US8334239B2 (en) 2007-07-10 2012-12-18 The Board Of Regents Of The University Of Texas System High affinity VEGF-receptor antagonists
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
CN101970012A (zh) * 2007-09-14 2011-02-09 日东电工株式会社 药物载体
WO2009048909A1 (en) * 2007-10-08 2009-04-16 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapies
CA2705152C (en) 2007-11-09 2016-10-11 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
US20090291083A1 (en) * 2008-01-07 2009-11-26 Patrys Limited Barb4 target, antibody designated barb4, barb4 related antibodies, and methods of making and using same
RU2531754C2 (ru) 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
US20110189093A1 (en) * 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
BRPI0920743A2 (pt) 2008-10-01 2016-09-20 Quintessence Biosciences Inc ribonucleases terapeuticas
ES2712732T3 (es) * 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
EP2229951A1 (en) * 2009-03-08 2010-09-22 Stichting Katholieke Universiteit Methods for the treatment or prevention of systemic sclerosis
SG10201810743WA (en) 2009-06-03 2018-12-28 Immunogen Inc Conjugation methods
AU2010325969B2 (en) 2009-12-02 2016-10-20 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
EP2571992B1 (en) 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
ME03353B (me) 2011-03-29 2019-10-20 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
BR112015021866A2 (pt) 2013-03-15 2017-08-29 Bayer Healthcare Llc Domínios de gla como agentes direcionadores
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
ES2843324T3 (es) 2014-11-18 2021-07-16 Maximum Fidelity Surgical Simulations Llc Reconstitución de la circulación post mortem
US10335495B2 (en) 2014-12-04 2019-07-02 Celgene Corporation Biomolecule conjugates
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
CN108367048B (zh) 2015-10-02 2022-08-12 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
US20170189548A1 (en) 2015-11-25 2017-07-06 Immunogen, Inc. Pharmaceutical formulations and methods of use thereof
US20190248920A1 (en) 2016-09-23 2019-08-15 Csl Limited Coagulation factor binding proteins and uses thereof
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
EP3658186A4 (en) 2017-07-24 2020-08-12 Rutgers, The State University of New Jersey FUSION MOLECULES TARGETING PHOSPHATIDYLSERINE AND THEIR METHODS OF USE
US11446365B2 (en) 2017-08-09 2022-09-20 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
EP3679129A1 (en) 2017-09-05 2020-07-15 GLAdiator Biosciences, Inc. A method of intracellular delivery
WO2019094959A1 (en) 2017-11-13 2019-05-16 Fernandez Joss Reconstitution of post mortem circulation, specialized methods and procedures
US11716989B2 (en) 2019-04-16 2023-08-08 Maximum Fidelity Surgical Simulations, LLC Cadaver preservation systems and methods
US11915610B2 (en) 2019-05-15 2024-02-27 Maximum Fidelity Surgical Simulations, LLC Cadaverous heart model
US12433876B2 (en) 2019-08-30 2025-10-07 University Of Rochester Septin inhibitors for treatment of cancers
JP2024511277A (ja) 2021-02-19 2024-03-13 メビオン・メディカル・システムズ・インコーポレーテッド 粒子線治療システムのためのガントリー
CN114807032B (zh) * 2022-05-20 2023-09-12 南京大学 地塞米松诱导中性粒细胞产生的细胞外囊泡在制备治疗消炎药物中的应用
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4925922A (en) 1983-02-22 1990-05-15 Xoma Corporation Potentiation of cytotoxic conjugates
FR2566271B1 (fr) 1984-06-20 1986-11-07 Sanofi Sa Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention
US4837003A (en) * 1984-09-13 1989-06-06 Mallinckrodt, Inc. Radiolabeled antibody fragments
CA1289880C (en) 1985-12-06 1991-10-01 Jeffrey L. Winkelhake Anti-human ovarian cancer immunotoxins and methods of use thereof
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
FR2601679B1 (fr) 1986-07-15 1990-05-25 Sanofi Sa Immunotoxines, procede de preparation et compositions pharmaceutiques en contenant
AU613316B2 (en) 1986-09-12 1991-08-01 Genentech Inc. Improved recombinant expression
ES2073391T3 (es) 1986-11-04 1995-08-16 Genentech Inc Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre.
IE81149B1 (en) 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
GB8800077D0 (en) 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US4867962A (en) 1988-02-26 1989-09-19 Neorx Corporation Functionally specific antibodies
US5024834A (en) 1988-07-12 1991-06-18 Cetus Corporation Thioether linked immunotoxin conjugates
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
IL91933A (en) 1988-10-11 1994-12-29 Univ Southern California Vasoactive immunoconjugates useful for increasing the vascular permeability or the blood supply to neoplastic or otherwise diseased tissues
US5632991A (en) * 1988-11-14 1997-05-27 Brigham & Women's Hospital Antibodies specific for E-selectin and the uses thereof
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5134075A (en) 1989-02-17 1992-07-28 Oncogen Limited Partnership Monoclonal antibody to novel antigen associated with human tumors
US5272263A (en) 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
DE4022010A1 (de) 1989-07-15 1991-01-17 Boehringer Ingelheim Int Ein antikoagulanz enthaltendes mittel
US5166319A (en) 1989-10-10 1992-11-24 Brunswick Corporation Interfacial condensation of bioactive compounds and the site-specific compounds and conjugates thereof
DE3937607A1 (de) 1989-11-11 1991-05-16 Boehringer Ingelheim Int Verwendung eines antikoagulanz zur behandlung von tumorerkrankungen
US5165923A (en) 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
US5627036A (en) 1989-12-27 1997-05-06 Boehringer Ingelheim International Gmbh Use of an anticoagulant as a diagnostic agent
ATE127925T1 (de) 1990-04-06 1995-09-15 Yamasa Shoyu Kk Verfahren zur bestimmung von antiphospholipid antikörpern.
DE69122777T2 (de) 1990-07-20 1997-04-10 Pharmacia & Upjohn Ab, Stockholm Zielgerichtete spezifische antikörper-superantigen konjugate und ihre präparation
WO1992004044A1 (en) * 1990-09-06 1992-03-19 Schering Corporation Use of il-4 to treat solid tumors
AU1269092A (en) 1991-01-24 1992-08-27 Cytel Corporation Monoclonal antibodies to elam-1 and their uses
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
US5399338A (en) * 1991-05-01 1995-03-21 University Of New Mexico Enhancement of abnormal tissue uptake of antibodies, tumor-specific agents or conjugates thereof for diagnostic imaging or therapy
US5632986A (en) 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
US5346991A (en) * 1991-06-13 1994-09-13 Genentech, Inc. Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6036955A (en) 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
PT627940E (pt) 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
US6329507B1 (en) * 1992-08-21 2001-12-11 The Dow Chemical Company Dimer and multimer forms of single chain polypeptides
ATE250138T1 (de) 1992-10-29 2003-10-15 Univ Australian Angiogenese-inhibierende antikörper
US5512269A (en) * 1993-06-09 1996-04-30 Burroughs Wellcome, Co. Method of treating retained pulmonary secretions
JP3664727B2 (ja) 1994-01-24 2005-06-29 ネオルクス コーポレイション 放射標識したアネキシン
US5968477A (en) 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
WO1995021812A1 (en) 1994-02-14 1995-08-17 Indiana University Foundation Aminophospholipid compositions and uses thereof
CA2185535C (en) 1994-04-11 2000-10-24 Christiaan Peter Maria Reutelingsperger A method for detecting and/or optionally quantifying and/or separating apoptotic cells in or from a sample
WO1995034315A1 (en) 1994-06-16 1995-12-21 Neorx Corporation Radiolabeled annexin-galactose conjugates
US5830448A (en) * 1994-06-16 1998-11-03 Genentech, Inc. Compositions and methods for the treatment of tumors
DE69519929T2 (de) * 1994-07-11 2001-05-23 Board Of Regents, The University Of Texas System Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen
EP0799050B1 (en) 1994-12-07 2004-08-11 Neorx Corporation Radiolabeled annexin-galactose cluster conjugates
US5658877A (en) 1995-05-18 1997-08-19 Wisconsin Alumni Research Foundation Method to treat endotoxin effects by administration of 33 kilodalton phospholipid binding protein
DE19541284C2 (de) 1995-11-06 1998-09-24 Kalden Joachim Robert Prof Dr Verfahren zur Immunmodulation
IL117223A0 (en) * 1996-02-22 1996-06-18 Yeda Res & Dev Antipathogenic polypeptides and compositions comprising them
JP2001503396A (ja) 1996-10-11 2001-03-13 アルザ コーポレイション 治療用リポソーム組成物および方法
EP0965597A4 (en) * 1996-12-27 2003-01-08 Mochida Pharm Co Ltd CELL MEMBRANE EFFECTIVE DRUGS
US5922688A (en) * 1997-01-10 1999-07-13 Board Of Regents, The University Of Texas System PEA3 is a tumor suppressor
US7001983B1 (en) * 1997-02-20 2006-02-21 Yeda Research And Development Co., Ltd. Antipathogenic synthetic peptides and compositions comprising them
US6005083A (en) 1997-03-28 1999-12-21 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
KR20010020443A (ko) * 1997-04-30 2001-03-15 캐서린 구 생체내 세포 치사를 이미지화시키는 방법
US6057435A (en) 1997-09-19 2000-05-02 Genentech, Inc. Tie ligand homologues
US20030060612A1 (en) * 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6300308B1 (en) * 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
AU2451199A (en) * 1998-01-07 1999-07-26 Human Genome Sciences, Inc. 36 human secreted proteins
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US7067109B1 (en) 1998-07-13 2006-06-27 Board Of Regents, The University Of Texas System Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids
DE69941031D1 (de) * 1998-11-12 2009-08-06 Novolytics Inc Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion
AU773420B2 (en) 1998-12-11 2004-05-27 Medarex, Inc. Prodrug compounds and process for preparation thereof
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
US6824780B1 (en) * 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
WO2001068709A1 (en) 2000-03-14 2001-09-20 Idec Pharmaceuticals Corporation Antibodies that bind phosphatidyl serine and a method of their use
US20030129223A1 (en) 2000-10-11 2003-07-10 Targesome, Inc. Targeted multivalent macromolecules
US20030133972A1 (en) 2000-10-11 2003-07-17 Targesome, Inc. Targeted multivalent macromolecules
IL139720A0 (en) * 2000-11-16 2002-02-10 Yeda Res & Dev Diastereomeric peptides and pharmaceutical compositions comprising them
CN100506284C (zh) 2001-10-19 2009-07-01 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
AU2002350623A1 (en) 2001-10-26 2003-05-06 The Scripps Research Institute Targeted thrombosis by tissue factor polypeptides
EP1476752A4 (en) * 2002-02-27 2008-02-13 Bio Merieux Inc METHOD FOR DIAGNOSING AND MONITORING HEMOSTATIC DYSFUNCTION, SEVERE INFECTION AND SYSTEMATIC INFLAMMATORY RESPONSE SYNDROME
WO2005019429A2 (en) * 2003-08-22 2005-03-03 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity

Similar Documents

Publication Publication Date Title
JP2010143941A5 (https=)
Byrne et al. Active targeting schemes for nanoparticle systems in cancer therapeutics
Lammers et al. Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy
Shinkai et al. Targeting hyperthermia for renal cell carcinoma using human MN antigenspecific magnetoliposomes
Huang et al. A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice
Raucher et al. Macromolecular drug carriers for targeted glioblastoma therapy: Preclinical studies, challenges, and future perspectives
CA2591914C (en) Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
Connell et al. Selective permeabilization of the blood–brain barrier at sites of metastasis
US6159443A (en) X-ray guided drug delivery
JP2002520297A5 (https=)
ES2529660T3 (es) Métodos de tratamiento en los que se utilizan las proteínas de unión a albúmina como dianas
Chen et al. A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma
Loi et al. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma
JP4576005B2 (ja) 腫瘍および炎症性疾患を選択的に治療するために用いられる、壊死を引き起こす物質と、壊死により活性化される物質との組み合わせ
MXPA05000652A (es) Anticuerpos seleccionados y peptidos de duramicina que se enlazan a fosfolipidos anionicos y aminofosfolipidos y sus usos en el tratamiento de infecciones virales y del cancer.
Yan et al. A carboxyl-terminated dendrimer enables osteolytic lesion targeting and photothermal ablation of malignant bone tumors
Toomajian et al. Magnetic particle imaging reveals that iron-labeled extracellular vesicles accumulate in brains of mice with metastases
JP2025066706A (ja) 薬物伝達と内在化効率が強化された薬物複合体
Khoshnejad et al. Vascular accessibility of endothelial targeted ferritin nanoparticles
Zamora et al. Combination of physicochemical tropism and affinity moiety targeting of lipid nanoparticles enhances organ targeting
Pinho et al. Stem cells as vehicles and targets of nanoparticles
Ruoslahti Access granted: iRGD helps silicasome-encased drugs breach the tumor barrier
Kapoor et al. Ligands for targeted drug delivery and applications
Muradova et al. Targeted-theranostic nanoparticles induce anti-tumor immune response in lung cancer
US20260048022A1 (en) Endothelial damage and nanoparticle targeting: compositions, processes, uses